Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis

StemGenex

Status: Unknown

Conditions: Multiple Sclerosis

Study type: Observational

Funder types: Industry

Identifiers

NCT02157064

ASCMS-01 (Other Identifier)

SVF01MS

Details and patient eligibility

About

The purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (SVF), has on the quality of life of people with multiple sclerosis (MS). SVF contains components with "regenerative" properties, including stem cells that may be capable of ameliorating specific disease conditions. This study is designed to evaluate quality of life changes in individuals with MS for up to 12 months following SVF treatment.

Enrollment: 221 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects scheduled for a stem cell/SVF treatment
• Subjects diagnosed with some form of multiple sclerosis
• Subjects between the ages of 18 and 65
• Subjects willing and able to sign informed consent
• Subjects willing and able to perform follow up interviews and surveys

Exclusion criteria

• Subjects for whom baseline data is not available
• Subjects with additional major health diagnoses
• Subjects that are pregnant or breastfeeding